SCHEMBL509848

SCHEMBL509848

CCCCCOC(=O)OC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.57
HCAR2 Q8TDS4 2/20 0.50
EPHX1 P07099 1/20 0.48
TSHR P16473 4/20 0.47
ALDH1A1 P00352 2/20 0.46
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPK1 P28482 1/20 0.44
RAD52 P43351 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ATM Q13315 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
FAAH O00519 1/20 0.43
LMNA P02545 1/20 0.43
ACHE P22303 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27569364 0.98 NAAA (0.61) NAAAHCAR2EPHX1TSHRALDH1A1
SCHEMBL27691921 0.98 NAAA (0.61) NAAAHCAR2EPHX1TSHRALDH1A1
SCHEMBL27556711 0.98 NAAA (0.61) NAAAHCAR2EPHX1TSHRALDH1A1
SCHEMBL22163821 0.98 NAAA (0.61) NAAAHCAR2EPHX1TSHRALDH1A1
SCHEMBL20576381 0.98 NAAA (0.61) NAAAHCAR2EPHX1TSHRALDH1A1
SCHEMBL28237562 0.94 NAAA (0.57) NAAAHCAR2EPHX1TSHRALDH1A1
SCHEMBL20678411 0.94 NAAA (0.57) NAAAHCAR2EPHX1TSHRALDH1A1
SCHEMBL40276 0.93 ALDH1A1 (0.54) NAAAHCAR2EPHX1TSHRALDH1A1
Methyl Alcohol SCHEMBL28202491 0.91 ALDH1A1 (0.52) NAAAHCAR2EPHX1TSHRALDH1A1
Bicarbonate SCHEMBL28257342 0.89 ALDH1A1 (0.50) NAAAHCAR2EPHX1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4330261-A1 USE OF FLUORESCEIN DICARBONATE DERIVATIVES AS A CELL MARKER Université Jean Monnet Saint-Étienne (FR) 2024-03-06 EP disclosed
WO-2023153303-A1 PHOTOCURABLE COMPOSITION, OPTICAL LAMINATE, OPTICAL ARTICLE, LENS, AND SPECTACLES 株式会社トクヤマ 2023-08-17 WO disclosed
WO-2022229353-A1 USE OF FLUORESCEIN DICARBONATE DERIVATIVES AS A CELL MARKER UNIVERSITE JEAN MONNET SAINT ETIENNE (FR) 2022-11-03 WO disclosed
CN-112513136-A Poly (pyrocarbonate) based polymer electrolytes for high voltage lithium ion batteries 罗伯特·博世有限公司 2021-03-16 CN disclosed
CN-108290834-A Process for producing thiocarboxylic ester 三菱化学株式会社 2018-07-17 CN disclosed
EP-2938190-B1 MACROCYCLIC PICOLINAMIDES AS FUNGICIDES DOW AGROSCIENCES LLC (US) 2017-11-08 EP disclosed
US-20170273306-A1 MACROCYCLIC PICOLINAMIDES AS FUNGICIDES DOW AGROSCIENCES LLC (US) 2017-09-28 US disclosed
US-9681664-B2 Macrocyclic picolinamides as fungicides DOW AGROSCIENCES LLC (US) 2017-06-20 US disclosed
EP-2938190-A1 MACROCYCLIC PICOLINAMIDES AS FUNGICIDES Dow AgroSciences LLC (US) 2015-11-04 EP disclosed
EP-1666480-B1 Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. RAQUALIA PHARMA INC (JP) 2014-10-01 EP disclosed
US-6710054-B2 CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS PFIZER INC 2004-03-23 US disclosed
EP-1199324-B1 Sealing gasket for closure and process for production of closure using the same TOYO SEIKAN KAISHA LTD (JP) 2003-09-03 EP disclosed
EP-1326864-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP disclosed
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2002-08-08 US disclosed
US-20020101043-A1 Sealing gasket for closure and process for production of closure using the same TOYO SEIKAN KAISHA, LTD. 2002-08-01 US disclosed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed
EP-1199324-A1 Sealing gasket for closure and process for production of closure using the same TOYO SEIKAN KAISHA LIMITED (JP) 2002-04-24 EP disclosed
EP-0557408-A4 IMIDAZOLIDINONE COMPOUNDS 1993-10-27 EP disclosed
EP-0557408-A1 IMIDAZOLIDINONE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1993-09-01 EP disclosed
WO-1992007567-A1 IMIDAZOLIDINONE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1992-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, OPRM1 NAAA 1664/4885HCAR2 493/4885EPHX1 429/4885
US-20170273306-A1 MACROCYCLIC PICOLINAMIDES AS FUNGICIDES FKBP14, FKBP2, CYP4F12 NAAA 2589/4885HCAR2 990/4885EPHX1 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.